Oral drug administration is essential for treating diverse diseases due to its acceptable route, non-invasiveness, minimal off-target side effects, versatility, and painless patient delivery. However, multiple drug accessibility is increasing currently but there is often a deficiency of indication in developing procedures with assessment of two diverse medicinal formulations. Oral administration of a novel antiepileptic drug, levetiracetam in grouping with either L-dopa unaccompanied or L-dopa/Ropinirole treatments was associated with dyskinesia. Altered shooting patterns of neurons relating to a compulsive harmonization process may back to the origin of dyskinesia. The current study aims to develop a dissolution technique and validate the antiparkinsonian drug-ropinirole and antiepileptic drug-levetiracetam tablets by RP-HPLC, which plays a major part in pharmaceutical formulations. The optimal dissolution conditions were experienced for the products respective to the pharmaceutical formulation and applied to assess the dissolution profiles. Ideal settings for the dissolution method were 500 mL of pH of 4.0 citrate buffer, 50 rpm and 250 nm for ropinirole tablets and 900 mL of distilled water, the rotation speed of paddle 50 rpm and 217 nm for levetiracetam tablets, then 3.84 and 3.87 minutes were set as the retention time of ropinirole and levetiracetam tablets, respectively. Technique optimization and validation process helps to reduce the bioequivalence of both dosage forms. The current study ensues detailed information on the drug release, even if there is a change in pH medium, filter, rpm, instrumentation, etc. Focusing on current pharmaceutical sciences, the proposed correlative dissolution study coupled with RP-HPLC analysis could offer a holistic insight into the performance of future oral drug delivery systems